CytomX Therapeutics (CTMX) Net Margin (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Net Margin came in at 177.89% in Q1 2026, down 22409.0% YoY from N/an in Q1 2025, and up 94.8% on a QoQ basis from 3419.91% in Q4 2025.
CytomX Therapeutics (CTMX) Net Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Net Margin data on file, last reported at 177.89% in Q1 2026.
- Quarterly Net Margin fell 22409.0% year-over-year to 177.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 155.6% (down 18380.0% YoY) and the FY2025 annual result came in at 26.73%, down 4981.0% from the prior year.
- Net Margin climbed to 177.89% in Q1 2026, from 3419.91% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 49.55% in Q4 2024 to a low of 3419.91% in Q4 2025.
- A 5-year average of 271.1% and a median of 14.09% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin jumped 33968 bps — and 2025, when it slumped 346946 bps.
- Tracing CTMX's Net Margin over 5 years: stood at 43.61% in 2022, then surged by 107 bps to 3.15% in 2023, then soared by 1475 bps to 49.55% in 2024, then sank by 7002 bps to 3419.91% in 2025, then soared by 95 bps to 177.89% in 2026.
- The last three Net Margin figures came in at 177.89% (Q1 2026), 3419.91% (Q4 2025), and 238.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -1,457.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,457.40% |
| Mar 31, 2026 | -177.89% |
| Dec 31, 2025 | -3,419.91% |
| Sep 30, 2025 | -238.62% |
| Jun 30, 2025 | -0.83% |
| Mar 31, 2025 | 46.20% |
| Dec 31, 2024 | 49.55% |
| Sep 30, 2024 | 17.16% |
| Jun 30, 2024 | -26.02% |
| Mar 31, 2024 | 33.26% |
| Dec 31, 2023 | 3.15% |
| Sep 30, 2023 | 11.34% |
| Jun 30, 2023 | -4.40% |
| Mar 31, 2023 | -14.09% |
| Dec 31, 2022 | -43.61% |
| Sep 30, 2022 | -260.73% |
| Jun 30, 2022 | -229.49% |
| Mar 31, 2022 | -353.77% |
| Dec 31, 2021 | -312.82% |
| Sep 30, 2021 | -337.16% |